Latest National Institute of Neurological Disorders and Stroke Stories

NeoPharm, Inc. (NASDAQ: NEOL), today announced that the Company has signed a Cooperative Research and Development Agreement (the "CRADA") with the National Institute of Neurological Diseases and Stroke (NINDS), a part of the National Institutes of Health (NIH) for research on a therapeutic agent for untreatable brain diseases in humans. Under the terms of the CRADA, NINDS will deliver NeoPharm's proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) ("IL-13"), in conjunction with a...

Lixte Biotechnology Holdings has announced that the National Institute of Neurological Disorders and Stroke, National Institutes of Health and Lixte have filed a joint patent application for a new cancer biomarker. The new biomarker, present in many common cancers, is a target of drugs being evaluated by Lixte and the National Institute of Neurological Disorders and Stroke (NINDS) for the treatment of brain tumors. John Kovach, president and CEO of Lixte, said: "Studies with the research...

EAST SETAUKET, N.Y., Aug. 19 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (BULLETIN BOARD: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte filed a joint patent application identifying a biomarker, present in many common cancers, that is a target of drugs being evaluated by Lixte and NINDS for the treatment of brain tumors. Dr. John S. Kovach, President and CEO of Lixte, said,...

A new study about National Institutes of Health research grants ranks Utah eighth among states for new business activity for every $1 million in NIH funding. The report from Families USA shows that Utah generated $2.3 million, above the national average of $2.21 million. The report said that in fiscal 2007, Utah received $153 million in funding, which led to the creation of 3,003 new jobs, $130 million in total wages and an average wage of $43,271 from those new jobs. Nationally, nearly...

The National Institute of Neurological Disorders and Stroke, National Institutes of Health, and Lixte Biotechnology Holdings have extended co-operative research and development agreement to develop drugs for the treatment of brain cancers. The co-operative research and development agreement, initiated in March 2006, was extended through September 2009. John Kovach, president and CEO of Lixte, said: "The scientific interaction with the research team at the molecular pathogenesis unit,...

EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (BULLETIN BOARD: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte Biotechnology Holdings, Inc. extended their Cooperative Research and Development Agreement (CRADA) to develop drugs for the treatment of brain cancers. The CRADA, initiated in March 2006 was extended through September 2009. Dr. John S. Kovach,...

Most people with a rare type of dementia called primary progressive aphasia (PPA) have a specific combination of prion gene variants, a new study shows. The study is the first to link the prion protein gene to this disorder. It was funded in part by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), and appears in the December 2005 issue of the Annals of Neurology.[1] The researchers, led by James A. Mastrianni, M.D., Ph.D.,...

Unlike younger patients, there's little need to increase doseHealthDay News -- Daily aches and discomfort may become more common with age, but elderly Americans shouldn't have to increase their dosage of narcotic pain relievers to keep up with the pain, researchers report. On the other hand, people under 50 years of age may need to ramp up their dosage of these opioid pain-relieving medicines -- drugs like morphine, OxyContin and Percocet -- to achieve ongoing relief, reports a study in the...

But one expert cautions that sleeping pills won't cure insomniaHealthDayNews -- Insomniacs can now try another sleeping pill for desperately needed slumber.Lunesta, from Sepracor Inc., is the latest entry into the sleep medication market, and it has the distinction of being the only such medication approved for long-term use by the U.S. Food and Drug Administration (FDA).About 60 million Americans a year have insomnia often or for extended periods, according to the National Institute of...

Overlooked glial cells help form synapses, study findsHealthDay News -- Abundant but poorly understood brain cells called glia turn out to be essential in the development of synapses -- critical connections that form between neurons in the brain during its development, according to a new study.While scientists have long known that glia supported neurons in adults, this is the first time that researchers have identified the role of glia in forming the connections between neurons, says...